The Developmental Therapeutics Program evolved from the more basic Cell Cycling and Signaling Program, which scored """"""""Outstanding"""""""" in prior renewal cycles ofthis Helen Diller Family Comprehensive Cancer Center support grant. The research themes ofthe Cell Cycling and Signaling Program were related to identification and validation of therapeutic targets. Many of these targets have subsequently moved into preclinical testing or are ready to be explored in early-stage clinical trials. The new Eariy Phase Clinical Trials Unit has created an ideal opportunity to translate these themes effectively, through the design and analysis of innovative research protocols. The Program comprises 32 members involving 13 different departments and brings together basic cancer biologists and physician scientists with the common goal of discovering and testing novel compounds and treatment strategies for cancer The Program themes are: 1) Targeting signal transduction pathways (RTKs, RAS, RAF/MAPK, Pl 3'kinase, and wnt) 2) Targeting DNA replication and genome integrity (cell cycle, telomerase, HDAC) 3) Angiogenesis 4) Apoptosis 5) Genetic determinants of sensitivity and resistance The wide range of expertise ofthe Program members will mutually enrich and complement the discoveries of individual investigators with the overall Program goal being to accelerate the transition from drug discovery to the approval of more effective and less toxic drugs for patients with cancer. Research in the Program spans from drug discovery, cell signaling, molecular pathology and bioimaging to pharmacogenomics, as well as clinical and population science with recent high impact publications in Nature, Nature Medicine, Nature Genetics, New England Journal of Medicine, Journal of Clinical Oncology, Journal of Biological Chemistry, JAMA, Proceedings of the National Academy of Science of the United States, and The Lancet. The Program has a sizable and increasing percentage of intra- and inter-programmatic publications, which reflect the thematic breadth of the work and the emerging efforts of strategic integration of its members. The Program had $7,271,609 total peer-reviewed support for the last budget year. The Program has 12% intra-programmatic and 13% inter-programmatic publications.
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
| Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014 |
| Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160 |
Showing the most recent 10 out of 192 publications
